Cargando…

The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients

The independent prognostic significance of isolated tumour cells in bone marrow is still a matter of debate. This study evaluated the possible association of bone marrow micrometastases with tumour progression and prognosis in patients affected by gastric cancer. Bone marrow aspirates from both ilia...

Descripción completa

Detalles Bibliográficos
Autores principales: de Manzoni, G, Pelosi, G, Pavanel, F, Di Leo, A, Pedrazzani, C, Durante, E, Cordiano, C, Pasini, F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364170/
https://www.ncbi.nlm.nih.gov/pubmed/11953846
http://dx.doi.org/10.1038/sj.bjc.6600211
_version_ 1782153886712201216
author de Manzoni, G
Pelosi, G
Pavanel, F
Di Leo, A
Pedrazzani, C
Durante, E
Cordiano, C
Pasini, F
author_facet de Manzoni, G
Pelosi, G
Pavanel, F
Di Leo, A
Pedrazzani, C
Durante, E
Cordiano, C
Pasini, F
author_sort de Manzoni, G
collection PubMed
description The independent prognostic significance of isolated tumour cells in bone marrow is still a matter of debate. This study evaluated the possible association of bone marrow micrometastases with tumour progression and prognosis in patients affected by gastric cancer. Bone marrow aspirates from both iliac crests were obtained from 114 consecutive patients operated on for gastric cancer. The specimens were stained with monoclonal antibody CAM 5.2 which reacts predominantly with cytokeratin filaments 8 and 19. Among 114 cases analysed, 33 cases (29%) had cytokeratine-positive cells in the bone marrow. There was no significant relationship between the presence of bone marrow micrometastases and site, depth of tumour invasion, lymph node metastases, presence of metastases. Patients with cytokeratine-positive cells had a trend towards a diffuse type histology (P=0.06). Among the 88 curatively resected patients, median survivals were 40 months and 36 months for cytokeratine-negative and cytokeratine-positive subsets respectively (P=0.9). Recurrence of the disease was observed in 39 cases (44.3%); 11 of 24 (45.8%) in the cytokeratine-positive subset and 28 of 64 (43.7%) in the cytokeratine-negative subset. In conclusion in our experience the presence of cytokeratine-positive cells in the bone marrow of curatively resected gastric cancer patients did not affect outcome and its independent prognostic significance remains to be proven before its official acceptance in the TNM classification. British Journal of Cancer (2002) 86, 1047–1051. DOI: 10.1038/sj/bjc/6600211 www.bjcancer.com © 2002 Cancer Research UK
format Text
id pubmed-2364170
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23641702009-09-10 The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients de Manzoni, G Pelosi, G Pavanel, F Di Leo, A Pedrazzani, C Durante, E Cordiano, C Pasini, F Br J Cancer Clinical The independent prognostic significance of isolated tumour cells in bone marrow is still a matter of debate. This study evaluated the possible association of bone marrow micrometastases with tumour progression and prognosis in patients affected by gastric cancer. Bone marrow aspirates from both iliac crests were obtained from 114 consecutive patients operated on for gastric cancer. The specimens were stained with monoclonal antibody CAM 5.2 which reacts predominantly with cytokeratin filaments 8 and 19. Among 114 cases analysed, 33 cases (29%) had cytokeratine-positive cells in the bone marrow. There was no significant relationship between the presence of bone marrow micrometastases and site, depth of tumour invasion, lymph node metastases, presence of metastases. Patients with cytokeratine-positive cells had a trend towards a diffuse type histology (P=0.06). Among the 88 curatively resected patients, median survivals were 40 months and 36 months for cytokeratine-negative and cytokeratine-positive subsets respectively (P=0.9). Recurrence of the disease was observed in 39 cases (44.3%); 11 of 24 (45.8%) in the cytokeratine-positive subset and 28 of 64 (43.7%) in the cytokeratine-negative subset. In conclusion in our experience the presence of cytokeratine-positive cells in the bone marrow of curatively resected gastric cancer patients did not affect outcome and its independent prognostic significance remains to be proven before its official acceptance in the TNM classification. British Journal of Cancer (2002) 86, 1047–1051. DOI: 10.1038/sj/bjc/6600211 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-04-08 /pmc/articles/PMC2364170/ /pubmed/11953846 http://dx.doi.org/10.1038/sj.bjc.6600211 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
de Manzoni, G
Pelosi, G
Pavanel, F
Di Leo, A
Pedrazzani, C
Durante, E
Cordiano, C
Pasini, F
The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients
title The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients
title_full The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients
title_fullStr The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients
title_full_unstemmed The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients
title_short The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients
title_sort presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364170/
https://www.ncbi.nlm.nih.gov/pubmed/11953846
http://dx.doi.org/10.1038/sj.bjc.6600211
work_keys_str_mv AT demanzonig thepresenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT pelosig thepresenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT pavanelf thepresenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT dileoa thepresenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT pedrazzanic thepresenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT durantee thepresenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT cordianoc thepresenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT pasinif thepresenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT demanzonig presenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT pelosig presenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT pavanelf presenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT dileoa presenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT pedrazzanic presenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT durantee presenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT cordianoc presenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients
AT pasinif presenceofbonemarrowcytokeratinimmunoreactivecellsdoesnotpredictoutcomeingastriccancerpatients